<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04997525</url>
  </required_header>
  <id_info>
    <org_study_id>2020-001218-39</org_study_id>
    <nct_id>NCT04997525</nct_id>
  </id_info>
  <brief_title>Estradiol and Progestrone Levels Following Frozen Embryo Transfer</brief_title>
  <acronym>ESTRO-FET</acronym>
  <official_title>Estradiol and Progesterone Levels in Early Pregnancy After Natural, Estradiol + Progesterone or Gonadotrophin Stimulated Frozen Embryo Transfer Cycle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Copenhagen University Hospital at Herlev</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Copenhagen University Hospital, Hvidovre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Copenhagen University Hospital at Herlev</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study is to investigate serum estradiol and progesterone levels in&#xD;
      women conceiving after natural, estradiol + progesterone or gonadotropin stimulated frozen&#xD;
      embryo tranfer (FET) cykles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrolled women will be either ovulatory or anovulatory when referred to fertility treatment.&#xD;
      Ovulatory women will be randomized to either natural cykle or estradiol + progesterone cykle&#xD;
      treatment for FET. Anovulatory women will be randomized to either estradiol + progesterone&#xD;
      cykle or gonadotropin cykle treatment for FET.&#xD;
&#xD;
      Included women will undergo weekly blood testing for serum estradiol and progesterone levels&#xD;
      until gestational age 9+6. They will also have routine vaginal ultrasound as well as&#xD;
      additional pregnancy ultrasounds performed.&#xD;
&#xD;
      Secondary obstetric outcomes will be investigated using the womens medical journals.&#xD;
&#xD;
      All the treatments are standard treatments in Denmark for FET.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum estradiol</measure>
    <time_frame>10 weeks</time_frame>
    <description>Blood samples in the first 10 weeks of pregnancy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum progesterone</measure>
    <time_frame>10 weeks</time_frame>
    <description>Blood samples in the first 10 weeks of pregnancy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gestational age at delivery</measure>
    <time_frame>At delivery</time_frame>
    <description>Weeks of pregnancy when the child has been delivered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child birth weight</measure>
    <time_frame>At delivery</time_frame>
    <description>Weight of the child at delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Obstetric complications</measure>
    <time_frame>9 months</time_frame>
    <description>Obsteric complication throughout pregnancy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child malformations</measure>
    <time_frame>9 months</time_frame>
    <description>Child malformations diagnosed in utero or at delivery</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Natural cycle</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These women will follow their natural cycle and receive one injection of hCG for stimulation of ovulation before embryo transfer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estradiol and progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These women will receive daily estradiol and progesterone tablets/capsules before and after embryo transfer. Treatment will continue until gestational age 9+6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gonadotropin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These women will receive daily gonadotropin injection before embryo tranfer. Ovulation will be stimulated using hCG injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estradiol Tablets</intervention_name>
    <description>Combined with progesterone</description>
    <arm_group_label>Estradiol and progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Combined with estradiol</description>
    <arm_group_label>Estradiol and progesterone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Follitropin Alfa</intervention_name>
    <description>Combined with hCG</description>
    <arm_group_label>Gonadotropin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chorionic Gonadotropin, Alpha</intervention_name>
    <description>In etiher natural cycle or combined with Follitropin Alfa</description>
    <arm_group_label>Gonadotropin</arm_group_label>
    <arm_group_label>Natural cycle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years &lt; 40 years&#xD;
&#xD;
          -  BMI &lt; 35 kg/m2&#xD;
&#xD;
          -  Normal wet smear within the past three years&#xD;
&#xD;
          -  Thawed blastocysts (day 5) after either IVF or ICSI treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  BMI &gt; 35 kg/m2&#xD;
&#xD;
          -  Day 6 blastocysts&#xD;
&#xD;
          -  Oocyte donation&#xD;
&#xD;
          -  HIV/ hepatitis&#xD;
&#xD;
          -  Undiagnosed vaginal bleeding&#xD;
&#xD;
          -  Uterine malformations&#xD;
&#xD;
          -  Persisting ovarian cysts&#xD;
&#xD;
          -  Tumors in Hypothalamus, pituitary, thyroid or adrenal&#xD;
&#xD;
          -  Previous breast cancer&#xD;
&#xD;
          -  BRCA1/2&#xD;
&#xD;
          -  Unregulated thyroid disease&#xD;
&#xD;
          -  Cardiovascular disease&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Present or previous chemotherapy/radiation therapy&#xD;
&#xD;
          -  Present or previous malignant disease&#xD;
&#xD;
          -  Smoking&#xD;
&#xD;
          -  Alcohol/drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pernille Fog Svendsen, DMSc</last_name>
    <phone>+4538689652</phone>
    <email>pernille.fog.svendsen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nina Freiesleben Mørch, Medical student</last_name>
    <phone>+4522211671</phone>
    <email>nina.freiesleben.moerch@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Herlev University Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pernille Fog Svendsen, DMSc</last_name>
      <phone>+4538689652</phone>
      <email>pernille.fog.svendsen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Nina Freiesleben Mørch, Medical student</last_name>
      <phone>+4522211671</phone>
      <email>nina.freiesleben.moerch@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hvidovre University Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2605</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mette Petri Lauritsen, MD, PhD</last_name>
      <phone>+4538620414</phone>
      <email>mette.petri.lauritsen.02@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 22, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Copenhagen University Hospital at Herlev</investigator_affiliation>
    <investigator_full_name>Pernille Fog Svendsen, DMSc</investigator_full_name>
    <investigator_title>DMSc</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

